FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

147 stories mentioning Eli Lilly and CompanyUpdated 4h ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca to treat adults with chronic lymphocytic leukemia across all lines of therapy. Lilly shares gained 7.2%.

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%.The iShares Biotechnology ETF (IBB) advanced 1.3%.In corporate news, Bio-Techne (TECH) shares jumped 20% after the company agreed to be acquired by Germany's Merck in an all-cash deal with an enterprise value of $11.3 billion.Eli Lilly (LLY) shares rose 1% after the company said its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.Kymera Therapeutics (KYMR) shares jumped 16% after the company said it has completed enrollment in a phase 2b trial of KT-621 in moderate to severe atopic dermatitis ahead of schedule.PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating postoperative pain treatment, the company said. The shares climbed 13%.

$KYMR$LLY$PRFX$TECH
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.6%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Bio-Techne (TECH) shares surged nearly 20% after it said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with an enterprise value of about $11.3 billion, as the German drugmaker aims to expand its presence in life sciences markets.Eli Lilly (LLY) shares rose 0.5% after it said Thursday its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday. Its shares jumped 17%.

$LLY$PRFX$TECH
Wire

Eli Lilly Says Foundayo, Zepbound Available Under Medicare GLP-1 Bridge Program

Eli Lilly (LLY) said Thursday its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.The program will run through Dec. 31, 2027, the company said.Foundayo or orforglipron, a daily pill, and Zepbound, or tirzepatide, KwikPen for single patient use are approved for adults with obesity, or overweight who also have weight-related medical problems.Lilly said about 20 million Medicare beneficiaries may meet the clinical criteria to access the medicines.Shares of Eli Lilly were up more than 1% in Thursday trading.Price: $1129.54, Change: $+12.28, Percent Change: +1.10%

$LLY
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.9%.The iShares Biotechnology ETF (IBB) climbed 2.4%.In corporate news, Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were up 0.6%.NRx Pharmaceuticals (NRXP) and two units are facing a lawsuit from Kadima Neuropsychiatry Institute for alleged breach of contract and misrepresentation regarding an acquisition agreement, the psychiatric clinic said Wednesday. NRx Pharmaceuticals shares fell 12%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Its shares were down 2.4%.InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. The shares jumped 10%.

$INMD$LLY$NRXP$PFE
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) climbed 2.2%.In corporate news, InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. Shares jumped 11%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Shares were down 3.1%.Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were shedding 0.5%.

$INMD$LLY$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks were advancing premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Absci (ABSI) stock was up 20% after the company priced its underwritten offering of 13.5 million shares at $7.41 apiece, expecting to raise $100 million in gross proceeds. The financing includes participation from Eli Lilly (LLY), Absci said.

$ABSI$LLY
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) advanced 1.5%.In sector news, the US Justice Department is expected to charge about 450 defendants in alleged healthcare fraud schemes worth more than $6.5 billion, marking its largest coordinated antifraud operation to date, The Wall Street Journal reported, citing federal officials.In corporate news, GE HealthCare Technologies (GEHC) is positioned for accelerating growth, driven by improving innovation, order momentum, and backlog, RBC Capital Markets said in a note. RBC started coverage of the company with an outperform rating and an $80 price target. GE HealthCare shares climbed 4.6%.Eli Lilly (LLY) and Astellas Pharma have entered into two separate asset sale agreements with Sangamo Therapeutics as part of Sangamo's voluntary Chapter 11 reorganization, the genomic medicine company said Tuesday. Lilly shares added 0.4%.Boundless Bio (BOLD) shares surged 85% after the company said it signed a definitive merger agreement with privately held biotech firm Serapha Bio.

$BOLD$GEHC$LLY
Wire

Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics

Eli Lilly (LLY) and Astellas Pharma have entered into two separate asset sale agreements with Sangamo Therapeutics as part of Sangamo's voluntary Chapter 11 reorganization, the genomic medicine company said Tuesday.Lilly's agreement covers Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform and the prion disease program ST-506, while Astellas' agreement involves the the Fabry disease program ST-920, Sangamo said.Lilly and Astellas will serve as "stalking horse" bidders in a court-supervised auction process, Sangamo said.Sangamo said it has secured commitment for debtor-in-possession financing to support ongoing operations.The petition was filed in the US Bankruptcy Court for the District of Delaware.Price: $1107.53, Change: $+3.50, Percent Change: +0.32%

$LLY
Wire

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable Sept. 10 to Holders of Record Aug. 14

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable Sept. 10 to Holders of Record Aug. 14

$LLY
Sectors

Sector Update: Healthcare Stocks Ease Late Afternoon

Healthcare stocks eased late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) also dropped 0.2%.In corporate news, Eli Lilly (LLY) acquired 4E Therapeutics, a neuroscience firm creating chronic-pain treatments. Lilly shares fell 1%.CAMP4 Therapeutics (CAMP) shares jumped 6.1% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares eased 0.1%.Oncolytics Biotech (ONCY) shares climbed 11% after the company received a US patent covering the pelareorep manufacturing process into 2044.

$CAMP$GSK$LLY$ONCY
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.2%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly (LLY) submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech (ONCY) shares jumped past 10% after it said Tuesday it has received a US patent covering the pelareorep manufacturing process into 2044.

$GSK$LLY$NVO$ONCY
Wire

Eli Lilly Acquires 4E Therapeutics

Eli Lilly (LLY) has acquired 4E Therapeutics, a neuroscience firm creating chronic pain treatments, 4E Therapeutics said Tuesday.The company said its lead compound, 4ET1103, showed a favorable safety profile in a phase 1 study.Financial terms were not disclosed.Price: $1124.39, Change: $-4.96, Percent Change: -0.44%

$LLY
Wire

CMS Proposes Permanent Framework for Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services on Friday proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price applicability year, transitioning from implementation through annual guidance to codified regulations.The proposal would govern future negotiations and renegotiations for high-cost, single-source drugs covered under Medicare Part D and Part B. CMS said it will select up to 20 additional negotiation-eligible drugs for the fourth cycle of negotiations and future cycles of the program.The rule also proposes a temporary pricing floor for certain small biotech drugs in 2029 and 2030.CMS said it has negotiated prices for 25 high-expenditure drugs during the program's first two years. Maximum fair prices for the first 10 selected drugs took effect Jan. 1, 2026.Price: $236.56, Change: $-4.31, Percent Change: -1.79%

$ABBV$JNJ$LLY$MRK$NVO
Insider Trading

Eli Lilly Insider Sold Shares Worth $2,876,925, According to a Recent SEC Filing

Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company, on June 10, 2026, sold 2,500 shares in Eli Lilly (LLY) for $2,876,925. Following the Form 4 filing with the SEC, Yuffa has control over a total of 29,804 common shares of the company, with 29,804 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/59478/000182600126000006/xslF345X05/wk-form4_1781209410.xml

$LLY
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 3%.In corporate news, Adial Pharmaceuticals (ADIL) shares surged 45% after it said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.Novartis (NVS) shares gained 4.2% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 2.8%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 2.9%.

$ADIL$LLY$NVO$NVS
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) climbed 1.9%.In corporate news, Novartis (NVS) shares gained 2.9% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 1.2%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 1.5%.

$LLY$NVO$NVS
Wire

Market Chatter: Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027

Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported Thursday, citing the Business Group on Health, a policy research group for large employers.Around 10% of employers who now cover GLP-1 drugs for weight-loss said they are planning to drop that coverage next year, the report said, citing the policy research group.Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $43.51, Change: $+0.72, Percent Change: +1.68%

$LLY$NVO
Wire

Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports

Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports

$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 1%, and Nuvalent surged 39%.Brookdale Senior Living (BKD) has reported May occupancy data in line with bullish comments by the company's management at a recent event and ahead of levels implied in RBC's model for Q2, RBC Capital Markets said in a note. Brookdale shares jumped past 8%.PTC Therapeutics (PTCT) shares climbed 3.3% after Citigroup upgraded the company's stock to buy and raised its price target to $108.Eli Lilly (LLY) signed a collaboration and licensing deal worth over $1 billion with AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.4%.

$BKD$GSK$LLY$NUVL$PTCT

Showing 41-60 of 147

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company